Manufacturer of Controlled Substances, Notice of Application, Lin Zhi International, Inc., 30332 [2013-12110]

Download as PDF 30332 Federal Register / Vol. 78, No. 99 / Wednesday, May 22, 2013 / Notices Drug Schedule 2C-E (2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine) (7509) ....................................................................................................................... 2C-H (2-(2,5-Dimethoxyphenyl)ethanamine) (7517) ................................................................................................................................... 2C-1(2-(4-lodo-2,5-dimethoxyphenyl)ethanamine) (7518) .......................................................................................................................... 2C-C (2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (7519) ...................................................................................................................... 2C-T-4 (2-(4-isopropylthio)-2,5-dimethoxyphenyl) ethanamine) (7532) ...................................................................................................... Dihydromorphine (9145) .............................................................................................................................................................................. Heroin (9200) ............................................................................................................................................................................................... Normorphine (9313) .................................................................................................................................................................................... Methamphetamine (1105) ........................................................................................................................................................................... 1-Phenylcyclohexylamine (7460) ................................................................................................................................................................. Phencyclidine (7471) ................................................................................................................................................................................... Phenylacetone (8501) ................................................................................................................................................................................. 1-Piperidinocyclohexanecarbonitrile (8603) ................................................................................................................................................ Cocaine (9041) ............................................................................................................................................................................................ Codeine (9050) ............................................................................................................................................................................................ Dihydrocodeine (9120) ................................................................................................................................................................................ Ecgonine (9180) .......................................................................................................................................................................................... Meperidine intermediate-B (9233) ............................................................................................................................................................... Noroxymorphone (9668) .............................................................................................................................................................................. The company plans to manufacture high purity drug standards used for analytical applications only in clinical, toxicological, and forensic laboratories. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR § 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than July 22, 2013. Dated: May 14, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. The company plans to manufacture bulk active pharmaceutical ingredients (APIs) for distribution to its customers. In reference to drug code 7360 (Marihuana), the company plans to bulk manufacture cannabidiol as a synthetic intermediate. No other activity for this drug code is authorized for this registration. Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR § 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than July 22, 2013. Dated: May 14, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–12114 Filed 5–21–13; 8:45 am] BILLING CODE 4410–09–P [FR Doc. 2013–12115 Filed 5–21–13; 8:45 am] DEPARTMENT OF JUSTICE BILLING CODE 4410–09–P Drug Enforcement Administration TKELLEY on DSK3SPTVN1PROD with NOTICES Manufacturer of Controlled Substances, Notice of Application, Austin Pharma, Llc. DEPARTMENT OF JUSTICE Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 28, 2013, Austin Pharma, LLC., 811 Paloma Drive, Suite C, Round Rock, Texas 78665– 2402, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Marihuana (7360), a basic class of controlled substance listed in schedule I. Manufacturer of Controlled Substances, Notice of Application, Lin Zhi International, Inc. VerDate Mar<15>2010 16:59 May 21, 2013 Jkt 229001 Drug Enforcement Administration Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 3, 2013, Lin Zhi International, Inc., 670 Almanor Avenue, Sunnyvale, California 94085, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk PO 00000 Frm 00066 Fmt 4703 Sfmt 9990 I I I I I I I I II II II II II II II II II II II manufacturer of the following basic classes of controlled substances: Drug Tetrahydrocannabinols (7370) 3,4-Methylenedioxymeth- amphetamine (7405). Cocaine (9041) ............................. Oxycodone (9143) ........................ Hydrocodone (9193) ..................... Methadone (9250) ........................ Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... Schedule I II II II II II II The company plans to manufacture the listed controlled substances as bulk reagents for use in drug abuse testing. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR § 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than July 22, 2013. Dated: May 14, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–12110 Filed 5–21–13; 8:45 am] BILLING CODE 4410–09–P E:\FR\FM\22MYN1.SGM 22MYN1

Agencies

[Federal Register Volume 78, Number 99 (Wednesday, May 22, 2013)]
[Notices]
[Page 30332]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-12110]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances, Notice of Application, Lin 
Zhi International, Inc.

    Pursuant to Sec.  1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on April 3, 2013, Lin Zhi 
International, Inc., 670 Almanor Avenue, Sunnyvale, California 94085, 
made application by renewal to the Drug Enforcement Administration 
(DEA) to be registered as a bulk manufacturer of the following basic 
classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370) 3,4-            I
 Methylenedioxymeth- amphetamine (7405).
Cocaine (9041).............................  II
Oxycodone (9143)...........................  II
Hydrocodone (9193).........................  II
Methadone (9250)...........................  II
Dextropropoxyphene, bulk (non-dosage forms)  II
 (9273).
Morphine (9300)............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
as bulk reagents for use in drug abuse testing.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR Sec.  1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than July 22, 2013.

    Dated: May 14, 2013.
 Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-12110 Filed 5-21-13; 8:45 am]
BILLING CODE 4410-09-P